At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,053 enrolled
Drug / intervention
AndroGel (testosterone gel) 1%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Energy, Sexual Desire and Body PropoRtions wIth AndroGel®, Testosterone 1% Gel Therapy (ESPRIT) in Hypogonadal Men
In Brief
An observational study evaluating AndroGel (testosterone gel) 1% for Hypogonadism. Completed, enrolled 1,053 participants across 331 sites in 9 countries.
Detailed Summary
Observational study with AndroGel®, Testosterone 1% gel therapy (ESPRIT) in hypogonadal men in the community over 6 months.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypogonadism
CountriesCanada, Croatia, Germany, Kuwait, Romania, Russia, Saudi Arabia, Slovenia, United Arab Emirates
CollaboratorsFovea
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedJun 2010
Primary CompletionAug 2010
TodayJul 2026
First PostedJun 14, 2010
Enrollment StartDec 1, 2007
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 16.1 years ago
Interventions
AndroGel (testosterone gel) 1%drug
AndroGel is topical testosterone gel 1% and is prescribed for once daily use.